<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932592</url>
  </required_header>
  <id_info>
    <org_study_id>20160000072</org_study_id>
    <nct_id>NCT02932592</nct_id>
  </id_info>
  <brief_title>evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients (AGREEMENT)</brief_title>
  <acronym>AGREEMENT</acronym>
  <official_title>evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the glycemic variations during acute coronary syndrome in non-diabetic patients
      (euglycemic, or with impaired fasting glucose, or with impaired glucose tolerance)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All nondiabetic patients with dysglycemia (fasting plasma glucose between 100 and 125 mg/dl)
      will be monitored with a device (Continuous Glucose Monitoring System) and all these patients
      will be undergone an oral glucose tolerance test after the discharge from this Unit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic status</measure>
    <time_frame>15 days</time_frame>
    <description>Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.
Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>15 days</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>15 days</time_frame>
    <description>HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>15 days</time_frame>
    <description>Triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>15 days</time_frame>
    <description>Lipoprotein (a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial damage</measure>
    <time_frame>15 days</time_frame>
    <description>sICAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial damage</measure>
    <time_frame>15 days</time_frame>
    <description>sVCAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>15 days</time_frame>
    <description>sRAGE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>15 days</time_frame>
    <description>sCD40L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>15 days</time_frame>
    <description>MPO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>15 days</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>15 days</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>15 days</time_frame>
    <description>TNF-alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart damage</measure>
    <time_frame>15 days</time_frame>
    <description>CPK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart damage</measure>
    <time_frame>15 days</time_frame>
    <description>I troponin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Dysglycemic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.
Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring System (i Pro 2 - Medtronic)</intervention_name>
    <description>This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.</description>
    <arm_group_label>Dysglycemic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nondiabetic patients

          -  acute coronary syndrome

        Exclusion Criteria:

          -  diabetic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
    <phone>+39 0382 502614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Giuseppe Derosa</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD</last_name>
      <phone>+39 0382 502614</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD, FESC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

